Stig Palm Selected Research

Ovarian Neoplasms (Ovarian Cancer)

1/2021	Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer.
1/2019	Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations.
12/2017	Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model.
4/2016	Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors.
11/2015	Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.
1/2015	Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.
7/2009	Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
11/2006	Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
11/2006	Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
8/2006	Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stig Palm Research Topics

Disease

28	Neoplasms (Cancer) 02/2024 - 03/2003
13	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 09/2003
5	Carcinoma (Carcinomatosis) 01/2017 - 07/2003
3	Ascites 12/2017 - 11/2005
2	Ovarian Epithelial Carcinoma 01/2023 - 01/2019
2	Body Weight (Weight, Body) 02/2020 - 12/2017
2	Residual Neoplasm 02/2020 - 11/2015
2	Breast Neoplasms (Breast Cancer) 06/2008 - 07/2004
1	Prostatic Neoplasms (Prostate Cancer) 02/2020
1	Neoplasm Metastasis (Metastasis) 02/2020
1	Intestinal Perforation 01/2019
1	Fatigue 01/2019
1	Anus Neoplasms (Anal Cancer) 06/2018
1	Neoplasm Micrometastasis 08/2013

Drug/Important Bio-Agent (IBA)

10	Monoclonal AntibodiesIBA 01/2019 - 03/2003
6	Astatine-211IBA 01/2021 - 10/2007
5	AntibodiesIBA 01/2021 - 09/2003
5	211At-labeled monoclonal antibody MX35IBA 01/2021 - 08/2006
4	Trastuzumab (Herceptin)FDA Link 06/2008 - 07/2003
3	Radioisotopes (Radionuclides)IBA 01/2018 - 06/2008
3	Immunoconjugates (Immunoconjugate)IBA 03/2016 - 12/2005
2	diazobenzenesulfonic acid (DASA)IBA 02/2024 - 09/2022
2	RadiopharmaceuticalsIBA 02/2024 - 09/2022
2	AntigensIBA 02/2020 - 01/2019
2	AstatineIBA 03/2016 - 07/2015
2	EpitopesIBA 01/2015 - 09/2003
1	SolutionsIBA 01/2024
1	Contrast MediaIBA 01/2023
1	Colloids (Colloid)IBA 01/2023
1	Thorium Dioxide (Thorotrast)IBA 01/2023
1	Rituximab (Mabthera)FDA Link 01/2021
1	farletuzumabIBA 01/2021
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 02/2020
1	Indicators and Reagents (Reagents)IBA 01/2019
1	TinIBA 03/2016
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2015
1	Hematoxylin (Haematoxylon)IBA 08/2013
1	Eosine Yellowish-(YS) (Eosin)IBA 08/2013
1	Liposomes (Liposome)IBA 12/2010
1	Actinium-225IBA 07/2004
1	SuspensionsIBA 03/2003

Therapy/Procedure

18	Therapeutics 02/2024 - 06/2008
14	Radioimmunotherapy 01/2023 - 09/2003
5	Aftercare (After-Treatment) 02/2020 - 11/2005
4	Drug Therapy (Chemotherapy) 01/2023 - 07/2009
2	Intravenous Injections 01/2021 - 01/2017
2	Catheters 01/2019 - 07/2009
2	Radiotherapy 06/2018 - 06/2008
1	Castration 02/2020
1	Transcutaneous Electric Nerve Stimulation (TENS) 08/2013
1	Intraperitoneal Injections 07/2003